Immunovant, Inc. (IMVT) research
Immunovant, Inc.- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $33.62
- As of
Immunovant, Inc. (IMVT): 4 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-09-03.
As of . Source: SEC EDGAR filings for IMVT. Method and limitations.
Share the IMVT intelligence card
See the full IMVT dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for IMVT on one page. Preview it with sample data, then open it live with a free account.
Preview the IMVT dossierActive signals for IMVT
- highCONSENSUS_BUY
4 tracked funds increased IMVT this 2026Q2, institutional consensus
- highCONSENSUS_BUY
3 tracked funds increased IMVT this 2026Q2, institutional consensus
- highINSTITUTIONAL_SURGE
MILLENNIUM MANAGEMENT LLC added +91% to IMVT (2026Q2)
- highINSTITUTIONAL_SURGE
RENAISSANCE TECHNOLOGIES LLC added +278% to IMVT (2026Q2)
- highINSTITUTIONAL_SURGE
CITADEL ADVISORS LLC added +172% to IMVT (2026Q2)
FREE, NO ACCOUNT
Every signal on IMVT, as it fires
You are seeing 5 of 11 signals recorded on IMVT since 2026-05-27.
The five above landed across 2 days. The other 6 were recorded on 3 other days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in IMVT (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| D. E. Shaw & Co., Inc.CUSIP 45258J102 · 2026Q2 | $47.8M | 0.02% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 45258J102 · 2026Q2 | $28M | 0.04% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 45258J102 · 2026Q2 | $12.7M | 0.00% | , |
| CITADEL ADVISORS LLCCUSIP 45258J102 · 2026Q2 | $6.2M | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, IMVT
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
IMVT against its peers
IMVT's return on equity of -59.3% ranks in the 24th percentile of 22 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-03-31.
| Metric | IMVT | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | n/a | 168M | n/a | 18 |
| Operating margin | n/a | -40.4% | n/a | 15 |
| Net margin | n/a | -40.4% | n/a | 15 |
| Return on equity | -59.3% | -25.4% | 24 | 22 |
Peers (24): RYTM, ALKS, BLTE, SYRE, LGND, IONS, CNTA, GRAL, CGON, PRAX, SRRK, KOD, MIRM, ABVX, ORKA, TGTX, TVTX, COGT, PCVX, PTCT, CRSP, CAI, CRNX, IBRX. Left out: BCHMY (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-03-31. Every figure is one full fiscal year read from one annual filing (IMVT: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
See more IMVT signals as they fire
Kresmion publishes filings, 13F flows, on-chain whale activity, and cross-asset signals in real time. Open a live board scoped to IMVTand get the insider, 13F, options, and confluence read in one view.